Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder

Annals of Clinical Psychiatry

Volumn 15, Issue 3-4, 2003, Pages 187-192

  Papakostas, George I ^a   Petersen, Timothy ^a   Denninger, John W ^a   Montoya, Heidi D ^a   Nierenberg, Andrew A ^a   Alpert, Jonathan E ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adverse; Event; Fluoxetine; Outcome

Indexed keywords

FLUOXETINE;

ADULT; AKATHISIA; ANOREXIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RESTLESSNESS; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; LIKELIHOOD FUNCTIONS; LITHIUM CARBONATE; MALE; MIDDLE AGED; PATIENT DROPOUTS; PERSONALITY INVENTORY; RISK FACTORS; TREATMENT OUTCOME;

EID: 0842284007     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:ACLI.0000008172.20590.22     Document Type: Conference Paper

References (11)

1. Ackerman DL, Greenland S, Bystritsky A, Small G: Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. J Clin Psychopharmacol 2000; 20:658-665
2. Dittman RW, Linden M, Osterheide M, Schaa B, Ohnmacht U, Weber HJ: Antidepressant drug use: Differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine. Pharmacopsychiatry 1997; 30:28-34
3. Linden M, Gothe H, Dittman RW, Schaaf B: Early termination of antidepressant drug treatment. J Clin Psychopharmacology 2000; 20:523-530
4. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD: A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182:547-551
5. Spitzer RL, Williams JB, Gibbon M, First, MB: Structured Clinical Interview for DSM-III-R-Patient edition (SCID-P). New York: New York State Psychiatric Institute, Biometrics Research Department; 1989
6. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
7. Denninger J, Mahal Y, Merens W, Alpert JE, Nierenberg AA, Yeung A, Fava M: The Relationship Between Somatic Symptoms and Depression. American Psychiatric Association Annual Meeting, Philadelphia, 2002
8. Dunn OJ: Multiple comparisons among means. J Am Stat Assoc 1961; 56:52-64
9. Beasley CM, Jr, Nilsson ME, Gonzales JS: Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20 mg dose. J Clin Psychiatry 2000; 61:722-728
10. Benkert O, Szegeli A, Wetzel H, Staab HJ, Meister W, Phillipp, M: Dose escalaton vs. continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 95:288-296
11. Beasley CM, Bosomworth JC, Wernicke JF: Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990; 26:18-24